Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2005

View Archived Issues

Merck describes novel compounds for obesity and related eating disorders

NP-0361 shows promise in the treatment of Alzheimer's

In vivo evidence that a 5-HT2A/2C receptor agonist elevates sexual activity

Methylene blue in the treatment of prolonged pharmaco-induced erection

Selective 5-HT6 receptor antagonist improves memory acquisition in rats / News in Context

OncoGenex Technologies and Isis broaden antisense partnership

Cetrorelix enters development for endometriosis and BPH

FDA Advisory Committee recommends approval of Boostrix

Sonus reviews Tocosol Paclitaxel progress, terminates Synt:em acquisition

Arpida set to advance injectable iclaprim into global phase III program

PEP-005 Topical enters phase II

Phase I study of XL-880 in solid tumor patients

Neurogenetics changes name to TorreyPines Therapeutics

Positive results from pilot PK study of ondansetron lingual spray

Two CS-917 studies terminated after serious adverse events

TAP compound huMy9-6-DM4 enters clinical testing

GTC Biotherapeutics awaits EMEA comments regarding ATryn MAA

Galangin shows promise as a treatment for bladder dysfunction / News in Context

Serono identifies 80 genes involved in MS

First clinical evidence for the benefits of R-pramipexole in ALS

New data presented on the PK profile of alvimopan and DA-6034 at the ASCPT

The STAR study confirms the greater efficacy of solifenacin in OAB

BXL-628 reduces prostate volume in patients with BPH

Phase II trial on the efficacy of tgAAVCF in cystic fibrosis fails to meet primary endpoint

New treatments for bone disorders reported in patent literature

Recent patents describe treatments for cancer

New mechanism described for angiogenesis inhibitors TNP-470 and caplostatin

Antitumor activity of the Plk-1 inhibitor ON-01910 / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...